uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B – Nasdaq
uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia BNasdaqLEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 31, 2017 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leading gene therapy compan… Continue reading
